Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).

Although the mice treated with VV-α-TIGIT only showed a trend of lower tumor volume compare to mice treated with VV-Control ( P > 0.05) ( Fig. 5 F ), these mice demonstrated a significantly longer survival time than mice treated with VV-Control ( P <0.01) ( Fig. 5 G ).

also in 47,116 other papers

Although tumor microvascular density (MVD) showed a decreasing trend in the group of mice treated with VV-α-TIGIT compare to VV-Control or PBS, no significant difference was observed between these three groups ( Fig. 5 J ).

also in 40,617 other papers